Zhang Xue, Wang Shuoting, Wang Fujue, Shen Qianqing, Jia Yongqian
Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, #37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan, China.
Leuk Res Rep. 2022 May 21;17:100326. doi: 10.1016/j.lrr.2022.100326. eCollection 2022.
Myeloid sarcoma (MS), is a rare extramedullary tumor with a poor prognosis and high recurrence rate. Microtransplantation is one of the alternative methods of traditional transplantation, which does not rely on HLA complete matching, has low toxicity and may retain part of graft-versus-leukemia (GVL) effect. It has been reported that microtransplantation can significantly improve the survival rate of elderly AML patients. At present, there is no report on the application of micro transplantation in MS. We will report two cases of MS treated by micro transplantation. The disease-free survival was 66 months and 55 months respectively.
髓系肉瘤(MS)是一种罕见的髓外肿瘤,预后较差且复发率高。微小移植是传统移植的替代方法之一,它不依赖人类白细胞抗原(HLA)完全匹配,毒性低,且可能保留部分移植物抗白血病(GVL)效应。据报道,微小移植可显著提高老年急性髓系白血病(AML)患者的生存率。目前,尚无微小移植应用于MS的报道。我们将报告两例接受微小移植治疗的MS病例。无病生存期分别为66个月和55个月。